期刊文献+

二甲双胍对肝脏P糖蛋白表达的影响 被引量:1

下载PDF
导出
摘要 目的通过动物实验观察二甲双胍治疗前后肝细胞脂肪变性程度以及P糖蛋白(Pgp)表达的变化,探讨二甲双胍对脂肪肝的疗效及其可能机制。方法高脂饮食构建胆固醇代谢紊乱SD大鼠模型,随机分组后二甲双胍组给予二甲双胍[50 mg/(kg.d)和100 mg/(kg.d)]灌胃,生理盐水灌胃作为对照组。4周后大鼠眼底静脉丛取血,并快速处死,取肝脏。光学显微镜下观察肝脏组织切片中肝细胞脂肪变性程度,免疫组化分析肝脏Pgp表达,全自动生化分析仪测定血清及肝匀浆相关生化指标。结果二甲双胍组治疗后血三酰甘油、胆汁酸均较对照组下降(P<0.05);仅二甲双胍高剂量组观察到体重减轻,差异有显著性(P<0.05)。二甲双胍治疗后肝脏脂肪变性程度减少(P<0.05),肝组织匀浆三酰甘油和总胆固醇含量下降(P<0.05)。二甲双胍治疗可抑制肝脏Pgp的蛋白表达(P<0.05),且这一作用在二甲双胍高剂量组更明显(P<0.05)。结论二甲双胍可抑制高脂饮食喂养SD大鼠肝脏Pgp的表达,改善肝细胞脂肪变性程度及脂代谢紊乱,而这一作用呈剂量依赖性。
出处 《广东医学》 CAS CSCD 北大核心 2012年第2期172-174,共3页 Guangdong Medical Journal
基金 广东省社会发展领域科技计划项目(编号:93078)
  • 相关文献

参考文献7

  • 1ECKFORD P D,SHAROM F J.Interaction of the P-glycoprotein in multidrug efflux pump with cholesterol:effects on ATPase activity,drug binding and transport[J].Biochemistry,2008,47(51):13686-13698.
  • 2KVPREOS K E.ABCA1 promotes the de novo biogenesis of apolipoprotein CⅢ-containing HDL particles in vivo and modulates the severity of apolipoprotein CⅢ-induced hypertriglyceridemia[J].Biochemistry,2008,47(39):10491-10502.
  • 3陈世清,刘杞,孙航,唐琳,邓建川.二甲双胍对胰岛素抵抗大鼠脂肪肝的影响[J].中华肝脏病杂志,2005,13(12):915-918. 被引量:13
  • 4LUKER G D,DAHLHEIMER J L,OSTLUND R E Jr,et al,Decreased hepatic accumulation and enhance desterification of cholesterol in mice deficient in mdr1a and mdr1b Pglycoproteins[J].J Lipid Res,2001,42(9):1389-1394.
  • 5THORNTON S J,WONG E,LEE S D,et al,Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice:implications for cholesterol metabolism[J].Lipids Health Dis,2008,7:21.
  • 6CONNELLY S L,PATTINSON J,GRUNDY M.P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors[J].Exp Hematol,2007,35(12):1793-1800.
  • 7RODRIGUES A C,CURI R,BRITTO L R,et al,Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells[J].Biochim Biophys Acta,2006,1760 (12):1866-1873.

二级参考文献12

  • 1陈世清,刘杞,孙航,张桂灵,石小枫.脂肪肝胰岛素抵抗大鼠模型的建立[J].中华肝脏病杂志,2005,13(2):105-108. 被引量:46
  • 2Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem, 1957, 226: 4977509.
  • 3Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 1999, 94: 2467-2474.
  • 4Hundal RS, Inzucchi SE. Metformin: new understandings, new uses.Drugs, 2003, 63: 1879-1894.
  • 5Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358: 893-894.
  • 6Uygun A, Kadayifci A, Isik AT, et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2004, 19: 537-544.
  • 7Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology, 2004, 40: 185-194.
  • 8McClain CJ, Barve S, Deaciuc I, et al. Cytokines in alcoholic liver disease. Semin Liver Dis, 1999, 19: 205-219.
  • 9Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem, 2004,279: 32345-32353.
  • 10Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis:summary of an AASLD Single Topic Conference. Hepatology, 2003,37: 1202-1219.

共引文献12

同被引文献15

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部